Skip to content

To compare the oral steroids versus intravenous steroids as a first line therapy for treatment of Acute severe ulcerative colitis.

To study the efficacy of oral corticosteroid compared to intravenous corticosteroid as a first line therapy for treatment of Acute severe ulcerative colitis. - NIL

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/064590
Enrollment
60
Registered
2024-03-21
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K518- Other ulcerative colitis

Interventions

Intervention1: Oral corticosteroids: Equivalent dose of oral corticosteroids (80mg/d) will be given for 3-6 days to the intervention arm compared to IV corticosteroids (60mg/d) in the standard arm Con

Sponsors

PGIMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosed cases of UC by endoscopy and biopsy 2. Patients with acute severe ulcerative colitis

Exclusion criteria

Exclusion criteria: 1. Patients with Hb less than 8g/dl 2. Patients with serum albumin levels less than 2.5 g/dl 3. Patients with sepsis precluding the use of corticosteroids with any two of the three criteria Fever Temp more than 100 F, TLC less than 4000/cumm or more than 12000/cumm, raised procalcitonin (more than 1 pg/dL) 4. Patients having more than 10 blood mixed stools 5. Patients having megacolon or toxic megacolon on abdominal x-ray 6. Patients with abdominal tenderness or features of impending perforation 7. Patients who have had any flare requiring corticosteroids in the preceding 3 months from inclusion 8. Patients with prior history of failure of response to intravenous corticosteroids for severe flare of ulcerative colitis 9. Patients already receiving oral corticosteroid at the time of inclusion 10. Patient who have received more than 1 dose of IV Corticosteroid during index admission 11. Poor performance status (ECOG 3) 12. Patients with suspected or proven malignancy of any organ and GI malignancy 13. Inclusion any other drug trial in last 03 months affecting outcome of current trial 14. Not willing to participate in the trial and sign the informed consent 15. Pregnant and lactating females 16. Patients with prior colonic surgery due to any cause.

Design outcomes

Primary

MeasureTime frame
clinical remission (defined as stool frequency less than or equal to 3 with no blood)Timepoint: Day 3 and 6

Secondary

MeasureTime frame
Gastrointestinal side effects of steroidTimepoint: Index admission;Number of subjects achieving Partial responseTimepoint: day 3;Requirement of second line medical therapy in both the groupsTimepoint: 3 months;Requirement of second line medical therapy in both the groups during the initial admissionTimepoint: During index admission;Requirement of surgeryTimepoint: 3 months;Requirement of surgery during the initial admissionTimepoint: During index admission;Total hospital stayTimepoint: During index admission

Countries

India

Contacts

Public ContactRitesh Acharya

PGIMER, Chandigarh

anupam.pgi@gmail.com9530720546

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026